The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease

American Journal of Geriatric Psychiatry

Volumn 6, Issue 2 SUPPL., 1998, Pages

  Cummings, Jeffrey L ^a   Back, Carla ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR STIMULATING AGENT; PSYCHOTROPIC AGENT;

AGITATION; ALZHEIMER DISEASE; ANXIETY NEUROSIS; APATHY; BEHAVIOR DISORDER; CHOLINERGIC SYSTEM; DEPRESSION; HUMAN; HYPOTHESIS; NEUROPSYCHIATRY; PSYCHOSIS; REVIEW; SYMPTOMATOLOGY;

EID: 0031949925     PISSN: 10647481     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019442-199821001-00009     Document Type: Article

References (72)

1. Bartus RT, Dean III RL, Beer B, et al: The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217:408-417
2. Coyle JT, Price DL, DeLong MR: Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 1983; 219:1184-1190
3. Cummings JL, Benson DF: Dementia: A Clinical Approach, 2nd Edition. Boston, Butterworths-Heinemann, 1992
4. Mohs RC, Davis BM, Johns CA, et al: Oral physostigmine treatment of patients with Alzheimer's disease. Am J Psychiatry 1985; 142:28-33
5. Davis KL, Thai LJ, Gamzu ER, et al: A double-blind placebo-controlled multicenter study of tacrine for Alzheimer's disease. N Engl J Med 1992; 327:1253-1259
6. Farlow M, Gracon SI, Hershey LA, et al: A controlled trial of tacrine in Alzheimer's disease. JAMA 1992; 268:2523-2529
7. Knapp MJ, Knopman DS, Solomon PR, et al: A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994; 271:985-991
8. Rogers SL, Friedhoff LT, and the Donepezil Study Group: The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a U.S. multicentre, randomized, double-blind, placebocontrolled trial. Dementia 1996; 7:293-303
9. Tariot PN, Schneider L: Contemporary treatment approaches to Alzheimer's disease. Consult Pharm 1996; 11:16-24
10. Cummings JL, Kaufer DI: Neuropsychiatrie aspects of Alzheimer's disease: the cholinergic hypothesis revisited. Neurology 1996; 47:876-883
11. Davies P, Maloney AJF: Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976; 2:1403
12. Perry EK, Perry RH, Blessed G, et al: Necropsy evidence of central cholinergic deficits in senile dementia. Lancet 1977; 1:189
13. Spillane JA, White P, Goodhardt MJ, et al: Selective vulnerability of neurons in organic dementia. Nature 1977; 266:558-559
14. White P, Goodhardt MJ, Keet JP, et al: Neocortical cholinergic neurons in elderly people. Lancet 1977; 1:668-671
15. Davies P: Studies on the neurochemistry of central cholinergic systems in Alzheimer's disease, in Alzheimer's Disease: Senile Dementia and Related Disorders, edited by Katzman R, Terry RD, Bick KL. New York, Raven, 1978, pp 453-459
16. Procter AW, Lowe SL, Palmer AM, et al: Topographical distribution of neurochemical changes in Alzheimer's disease. J Neurol Sci 1988; 84:125-140
17. Goyal RK: Muscarinic receptor subtypes. Physiology and clinical implications. N Engl J Med 1989; 321:1022-1029
18. Marsh DC, Flynn DD, Potter LT: Loss of M2 muscarinic receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation. Science 1985; 228:1115-1117
19. Perry EK, Perry RH, Smith CJ, et al: Cholinergic receptors in cognitive disorders. Can J Neurol 1986; 13:521-527
20. Taylor P, Brown JH: Acetylcholine, in Basic Neurochemistry: Molecular, Cellular, and Medical Aspects, 5th Edition, edited by Siegel GJ, Agranoff BW, Albers RW, et al. New York, Raven, 1994, pp 231-281
21. Ehlert FJ, Roeske WR, Yamamura HI: Molecular biology, pharmacology, and brain distribution of subtypes of muscarinic receptors, in Psychopharmacology: The Fourth Generation of Progress, edited by Blood FE, Kupfer DJ. New York, Raven, 1995, pp 111-124
22. Whitehouse PJ, Price DL, Clark AW, et al: Alzheimer's disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981; 10:122-126
23. Nieuwenhuys R: Chemoarchitecture of the Brain. New York, Springer-Verlag, 1985
24. Mesulam M-M, Mufson EJ: Neural inputs into the nucleus basalis of the substantia innominata (Ch4) in the rhesus monkey. Brain 1984; 107:253-274
25. Mesulam M-M, Mufson EJ, Levey AI, et al: Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. J Comp Neurol 1983; 214:170-197
26. Zubenko GS, Moossy J, Martinez J, et al: Neuropathologic and neurochemical correlates of psychosis in primary dementia. Arch Neurol 1991; 48:619-624
27. Victoroff J, Zarow C, Mack WJ, et al: Physical aggression is associated with preservation of substantia nigra pars compacta in Alzheimer's disease. Arch Neurol 1996; 53:428-434
28. Cummings JL, Gorman DG, Shapira J: Physostigmine ameliorates the delusions of Alzheimer's disease. Biol Psychiatry 1993; 33:536-541
29. Perry EK, Kerwin J, Perry RH, et al: Cerebral cholinergic activity is related to the incidence of visual hallucinations in senile dementia of Lewy body type. Dementia 1990; 1:2-4
30. Cummings JL, Diaz C, Levy M, et al: Neuropsychiatrie syndromes in neurodegenerative diseases: frequency and significance. Seminars in Neuropsychiatry 1996; 1:241-247
31. Cummings JL, Victoroff JI: Noncognitive neuropsychiatric syndromes in Alzheimer's disease. Neuropsychiatry, Neuropsychology, and Behavioral Neurology 1990; 3:140-158
32. Mega M, Cummings JL, Fiorello T, et al: The spectrum of behavioral changes in Alzheimer's disease. Neurology 1996; 46:130-135
33. Wragg RE, Jeste DV: Overview of depression and psychosis in Alzheimer's disease. Am J Psychiatry 1989; 146:577-587
34. Cohen-Mansfield J, Billig N: Agitated behaviors in the elderly, I: a conceptual overview. J Am Geriatr Soc 1986; 34:711-721
35. Reisberg B, Borenstein J, Salob SP, et al: Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry 1987; 48:9-15
36. Flynn FG, Cummings JL, Gornbein J: Delusions in dementia syndromes: investigation of behavioral and neuropsychological correlates. J Neuropsychiatry Clin Neurosci 1991; 3:364-370
37. Petry S, Cummings JL, Hill MA, et al: Personality alterations in dementia of the Alzheimer type. Arch Neurol 1988; 45:1187-1190
38. Rubin EH, Kinscherf DA: Psychopathology of very mild dementia of the Alzheimer type. Am J Psychiatry 1989; 146:1017-1021
39. Burns A, Jacoby R, Levy R: Psychiatric phenomena in Alzheimer's disease. III: disorders of mood. Br J Psychiatry 1990; 157:81-86
40. Cummings JL, Ross W, Absher J, et al: Depressive symptoms in Alzheimer's disease: assessment and determinants. Alzheimer Dis Assoc Disord 1995; 9:87-93
41. Weiner MF, Edland SD, Luszczynska H: Prevalence and incidence of major depression in Alzheimer's disease. Am J Psychiatry 1994; 151:1006-1009
42. Migliorelli R, Teson A, Sabe L, et al: Prevalence and correlates of dysthymia and major depression among patients with Alzheimer's disease. Am J Psychiatry 1995; 152:37-44
43. Pearlson GD, Ross CA, Lohr WD, et al: Association between family history of affective disorder and the depressive syndrome of Alzheimer's disease. Am J Psychiatry 1990; 37:452-456
44. Rabins PV, Mace NL, Lucas MJ: The impact of dementia on the family. JAMA 1982; 248:333-335
45. Reisberg B, Franssen E, Sclan SG, et al: Stage-specific incidence of potentially remediable behavioral symptoms in aging and Alzheimer's disease. Bull Clin Neurosci 1989; 54:95-112
46. Mentis MJ, Weinstein EA, Horwitz B, et al: Abnormal brain glucose metabolism in the delusional misidentification syndromes: a positron emission tomography study in Alzheimer's disease. Biol Psychiatry 1995; 38:438-449
47. Starkstein SE, Vazquez S, Petracca G, et al: A SPECT study of delusions in Alzheimer's disease. Neurology 1994; 44:2055-2059
48. Sultzer DL, Mahler ME, Mandelkern MA, et al: Psychiatric symptoms are associated with regional cortical metabolism in Alzheimer's disease. J Neuropsychiatry Clin Neurosci 1995; 7:476-484
49. Levy M, Cummings JL, Fairbanks LA, et al: Longitudinal assessment of symptoms of depression, agitation, and psychosis in 181 patients with Alzheimer's disease. Am J Psychiatry 1996; 153:1438-1443
50. Roberts GW, Leigh PN, Weinberger DR: Neuropsychiatric Disorders. St. Louis, Wolfe, 1993
51. Sunderland T, Tariot PN, Cohen RM, et al: Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. Arch Gen Psychiatry 1987; 44:418-426
52. Gorman DG, Read S, Cummings JL: Cholinergic therapy of behavioral disturbances in Alzheimer's disease. Neuropsychiatr Neuropsychol Behav Neurol 1993; 6:229-234
53. Bodick N, Offen W, Levey AI, et al: Effects of xanomeline, a selective muscarinic agonist, on cognitive function and behavioral symptoms in Alzheimer's disease. Arch Neurol 1997; 54:465-473
54. Kotrla KJ, Chacko RC, Harper RG, et al: SPECT findings on psychosis in Alzheimer's disease. Am J Psychiatry 1995; 152:1470-1475
55. Ponton MO, Darcourt J, Miller BL, et al: Psychometric and SPECT studies in Alzheimer's disease with and without delusions. Neuropsychiatry, Neuropsychology, and Behavioral Neurology 1995; 8:264-270
56. Cummings JL: Psychosis in neurologic disease: neurobiology and pathogenesis. Neuropsychiatry, Neuropsychology, and Behavioral Neurology 1992; 5:144-150
57. Sunderland T, Tariot PN, Newhouse PA: Differential responsivity of mood, behavior, and cognition to cholinergic agents in elderly neuropsychiatric populations. Brain Res Rev 1988; 13:371-389
58. Perry EK, Marshall E, Kerwin J, et al: Evidence of a monoaminergic-cholinergic imbalance related to visual hallucinations in Lewy body dementia. J Neurochem 1990; 55:1454-1456
59. Kaufer DI, Cummings JL, Christine D: Differential neuropsychiatrie symptom responses to tacrine in Alzheimer's disease: relationship to dementia severity. J Neuropsychiatry Clin Neurosci, in press
60. Gauthier S, Bouchard R, Lamontagne A, et al: Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease: results of a Canadian double-blind, cross-over, multicenter study. N Engl J Med 1990; 322:1272-1276
61. Craig AH, Cummings JL, Fairbanks L, et al: Cerebral blood flow correlates of apathy in Alzheimer's disease. Arch Neurol 1996; 53:1116-1120
62. Kaufer DI, Cummings JL, Christine D: Effect of tacrine on behavioral symptoms in Alzheimer's disease: an open label study. J Geriatr Psychiatry Neurol 1996; 9:1-6
63. Bliwise DL, Tinklenberg J, Yesavage JA, et al: REM latency in Alzheimer's disease. Biol Psychiatry 1989; 25:320-328
64. Doerr P, Berger M: Physostigmine-induced escape from dexamethasone suppression in normal adults. Biol Psychiatry 1983; 18:261-288
65. Davis KL, Hollander E, Davidson M, et al: Induction of depression with oxotremorine in patients with Alzheimer's disease. Am J Psychiatry 1987; 144:468-471
66. Whitehouse P: Intraventricular bethanechol in Alzheimer's disease: a continuing controversy. Neurology 1988; 38:307-308
67. Hollander E, Davidson M, Mohs RC, et al: RS 86 in the treatment of Alzheimer's disease: cognitive and biological effects. Biol Psychiatry 1987; 22:1067-1078
68. Cummings JL, Benson DF: The role of the nucleus basalis of Meynert in dementia: review and reconsideration. Alzheimer Dis Assoc Disord 1987; 1:128-145
69. Honer W, Prohovnik I, Smith G, et al: Scopolamine reduces frontal cortex perfusion. J Cereb Blood How Metab 1988; 8:635-641
70. Hunter R, Wyper DJ, Patterson J, et al: Cerebral pharmacodynamics of physostigmine in Alzheimer's disease investigated using single photonemission tomography. Br J Psychiatry 1991; 158:351-357
71. Schneider LS, Pollack VE, Lyness SA: A meta-analysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc 1990; 38:553-563
72. Sano M, Ernesto C, Thomas RG, et al: A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med 1997; 336:1216-1222